Taken together these data suggest that the adenoX-rCB11-A9 therapy may work by inducing a population of T cells to redirect their cytokine response to secrete predominantly IL-4, a cytokine known to ameliorate arthritis. This evidence concerns the gene IL4 and Arthritis.